Back to Agenda
[Session4]Think about the Data Quality of Clinical Trials by Learning the Regulation/Inspection
Session Chair(s)
![Koji Miyata](/_Images/member/Generic_Image_Missing-Profile.jpg)
Koji Miyata
Manager, Data Management Group, Data Science Development
Astellas Pharma Inc., Japan
![Yoko Tokunaga, MPharm](/_Images/member/Generic_Image_Missing-Profile.jpg)
Yoko Tokunaga, MPharm
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Speaker(s)
Updates on GCP inspection and Document-based inspection
Hiromichi Isaka, MPharm
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Office of Non-clinical and Clinical Compliance
![Han Yali](/_Images/member/Generic_Image_Missing-Profile.jpg)
China Specific DM Requirements
Han Yali
Pfizer (China) Research and Development Co., Ltd., China
![Priya Annamalai, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Inspection of FDA, EMA and MHRA: Points and Trends related to Clinical Data Management
Priya Annamalai, MS
Abbvie, United States
Senior Manager, RDQA Inspection Management
Have an account?